DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital glaucoma — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital glaucoma maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital glaucoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 1 subfamily B member 1 (CYP1B1) — CYP1B1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3PM0 · 2.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Primary congenital glaucoma is treated primarily with early surgery, not drugs. Medical management is described only as a temporising measure before definitive surgical intervention. One retrospective analysis of hypotensive medications in children with congenital glaucoma reports that the authors used their data to estimate the effectiveness of antiglaucoma agents from different pharmacological groups and to propose an algorithm for medicamental therapy, but the abstract gives no concrete numbers for response rates, survival, or sample size, and does not name any specific drug or compare outcomes.
Genetic findings come from a Swiss cohort of 18 patients from 14 unrelated families. Among 14 patients diagnosed with primary congenital glaucoma, six (43%) had pathogenic variants in CYP1B1, one (7%) had a frameshift variant in FOXC1, and seven (50%) had no genetic diagnosis. Three patients with glaucoma associated with nonacquired ocular anomalies included two with mild Axenfeld-Rieger syndrome who carried a FOXC1 duplication plus an additional FOXC1 missense variant, and one with a Barkan membrane who remained without a genetic diagnosis. One patient with juvenile open-angle glaucoma had a FOXC1 duplication. The authors recommend sequencing CYP1B1 and FOXC1 and analysing copy number variations in FOXC1 before extended gene panel sequencing.
No abstract reports a drug that improves long-term outcomes in congenital glaucoma. The 2013 and 2024 reviews both state that surgical intervention is the definitive treatment and that medical therapy is temporary. The 2013 medication study does not provide response rates or survival data. What is still missing is a randomised trial of any drug against surgery or placebo in children with congenital glaucoma, standardised outcome measures for intraocular pressure control and visual function in infants, and stratification by genetic subtype to test whether CYP1B1 or FOXC1 status predicts drug response.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Ophthalmology · 2013 · 34 citations · open access
Surgical Management in Primary Congenital Glaucoma: Four Debates
AbstractPrimary congenital glaucoma is a worldwide diagnostic and therapeutic challenge. Although medical management is often a temporizing measure, early surgical intervention is the definitive treatment. As the abundance of surgical treatment options continues to expand, the authors will compare and contrast the available options and attempt to provide a consensus on surgical management.
Exome Sequencing in a Swiss Childhood Glaucoma Cohort Reveals <i>CYP1B1</i> and <i>FOXC1</i> Variants as Most Frequent Causes
AbstractPurpose: The aim of this study was to investigate the molecular basis of childhood glaucoma in Switzerland to recommend future targeted genetic analysis in the Swiss population. Methods: Whole-exome sequencing and copy number variation (CNV) analysis was performed in a Swiss cohort of 18 patients from 14 unrelated families. Identified variants were validated by Sanger sequencing and multiplex ligation-dependent probe amplification. Breakpoints of structural variants were determined by a microarray. A minigene assay was conducted for functional analysis of a splice site variant. Results: A diagnosis of primary congenital glaucoma was made in 14 patients, of which six (43%) harbored pathogenic variants in CYP1B1, one (7%) a frameshift variant in FOXC1, and seven (50%) remained without a genetic diagnosis. Three patients were diagnosed with glaucoma associated with nonacquired ocular anomalies, of which two patients with mild ocular features of Axenfeld-Rieger syndrome harbored a FOXC1 duplication plus an additional FOXC1 missense variant, and one patient with a Barkan membrane remained without genetic diagnosis. A diagnosis of juvenile open-angle glaucoma was made in one patient, and genetic analysis revealed a FOXC1 duplication. Conclusions: Sequencing of CYP1B1 and FOXC1, as well as analysis of CNVs in FOXC1, should be performed before extended gene panel sequencing. Translational Relevance: The identification of the molecular cause of childhood glaucoma is a prerequisite for genetic counseling and personalized care for patients and families.
Primary Congenital Glaucoma in Children – Diagnosis and Procedure
AbstractThe paper presents problems related to congenital childhood glaucoma. The aetiology of the disease, symptoms and clinical picture are discussed. Diagnosis of congenital glaucoma in infants and children is performed under general anesthesia. Treatment of primary congenital glaucoma is mainly surgical. Children with congenital glaucoma require constant, systematic ophthalmic care and genetic counseling.
THE RETROSPECTIVE ANALYSIS OF THE APPLICATION OF HYPOTENSIVE MEDICATIONS FOR THE TREATMENT OF CONGENITAL GLAUCOMA IN THE CHILDREN BASED AT A PEDIATRIC SURGICAL DEPARTMENT
AbstractThe authors present their many-year experience with the application of modern hypotensive medications for the treatment of various forms of congenital glaucoma in the children depending on the stage of pathology and the degree of its compensation. The data obtained were used to estimate the effectiveness of antiglaucoma agents belonging to different pharmacological groups and propose the algorithm for medicamental therapy of congenital glaucoma in the children including young ones.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
